皮尔费尼在结合组织疾病相关的间歇性肺部疾病中的实际治疗效果
Xueting Yuan1,2,3,4, Chen Yu1,2,3,4, Shengyun Liu5
1Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Therapeutic advances in respiratory disease
|November 8, 2024
概括
皮尔芬尼 (PFD) 改善了连接组织疾病相关的间歇性肺病 (CTD-ILDs) 的肺功能. 这项现实研究表明,PFD有利于CTD-ILD患者,特别是患有系统性硬化症的患者.
科学领域:
- 肺部病理学 肺部病理学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮尔芬尼 (PFD) 是一种抗纤维素药物,主要用于治疗异常性肺纤维化.
- 它在结合性组织疾病相关的间歇性肺病 (CTD-ILDs) 中的疗效较少被理解.
- 这项研究调查了PFD在CTD-ILD患者的实际有效性.
研究的目的:
- 评估皮尔芬尼 (PFD) 在被诊断为CTD-ILD的患者的疗效.
- 分析PFD对这个患者群体肺功能参数的影响.
- 确定可能从PFD治疗中受益最多的患者子组.
主要方法:
- 使用了回顾性队列研究设计.
- 评估了289名CTD-ILD患者的临床特征和肺功能 (FVC,DLCO).
- 一个线性混合效应模型分析了PFD对6个月的肺功能变化的影响.
主要成果:
- 155名患者接受了PFD;134人作为对照.
- 6个月后,PFD组的强迫生命能力 (FVC) 和一氧化碳 (DLCO) 扩散能力显著改善.
- 亚组分析表明PFD在全身性硬化症 (SSc) -ILD,非UIP模式和限制性肺功能方面具有优异的影响.
结论:
- 现实数据证实,皮尔芬尼 (PFD) 在CTD-ILD患者中有效改善肺功能.
- 对于各种CTD-ILD亚型,PFD显示出治疗潜力.
- 对PFD在特定CTD-ILD中的作用进行进一步的研究是有必要的.
更多相关视频
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
153
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
153
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
141
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
141
Pulmonary Function Tests
311
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
311
Pleural Effusion II: Symptoms and Management
154
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
154
COPD: Pathogenesis and Clinical Features
235
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
235
Pulmonary Tuberculosis V
170
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
170


